ClinicalTrials.Veeva

Menu

Total Mesorectum Excision With Left Colic Artery Preservation for the Treatment of Rectal Cancer

N

Nanjing Medical University

Status

Unknown

Conditions

Rectal Cancer

Treatments

Procedure: a low ligation of IMA
Procedure: a high ligation of IMA

Study type

Interventional

Funder types

Other

Identifiers

NCT03724591
CRSYM201810

Details and patient eligibility

About

A randomized controlled clinical trial to compare the short and long term outcomes of left colic artery preservation for the treatment of Rectal Cancer

Full description

Rectal cancer is one of most frequently diagnosed cancers and one of the leading causes of cancer death around the world. Surgery remains the main treatment for rectal cancer. Anastomosis leakage (AL) is an unresolved, devastating and lethal complication after rectal cancer surgery and remains to be a serious difficulty for surgeons despite its causes, preventions and treatments having been extensively studied.

To achieve a radical dissection of lymph nodes, it is necessary to remove the central lymph nodes at the root of inferior mesenteric artery(IMA) trunk.From the perspectives of lymph nodes dissection and tension-free anastomosis, it is preferred to perform a high ligation of IMA. However, there is still a controversy whether IMA should be high ligated or not. The argument mainly focuses on whether this performance will compromise the blood perfusion of the proximal limb of the anastomosis leading to the occurrence of AL. Some studies suggested that a high ligation did not increase the rate of AL. There are still many surgeons prefer the transection of IMA distal to the left colic artery(LCA) with the intention to preserve a good blood supply of the left colon after the performance of lymph node dissection around IMA. Some studies suggests that the preservation of LCA in anterior resection for mid and low rectal cancer is associated with lower rates of AL. Further investigations are needed to resolve the controversy.

In this study, eligible patients will be randomly allocated to receive total mesorectal excision (TME) for rectal cancer either by a high ligation of IMA without preservation of left colic artery or a low ligation of IMA with preservation of left colic artery. Postoperative complications, including anastomosis leakage, anastomosis bleeding, will be recorded. Patients will be followed up every 3 months for 2 year, every 6 months for 3 years postoperatively to study the long term effects.

Enrollment

600 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients suitable for curative surgery over 18 years old;
  • American Society of Anesthesiologists(ASA) grade I-III;
  • Pathological diagnosis of rectal adenocarcinoma;
  • Patients suitable for abdominalperineal resection
  • Informed consent;
  • No history of familial adenomatous polyposis, ulcerative colitis or Crohn's disease.

Exclusion criteria

  • Pregnant patient;
  • History of psychiatric disease;
  • Use of systemic steroids;
  • Simultaneous multiple primary colorectal cancer;
  • Preoperative imaging examination results show:1. Tumor involves the surrounding organs and combined organ resection need to be done;2. distant metastasis;3. unable to perform R0 resection;
  • History of any other malignant tumor in recent 5 years;
  • Patients need emergency operation: mechanic ileus, perforation.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

600 participants in 2 patient groups

a high ligation of IMA
Experimental group
Description:
total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
Treatment:
Procedure: a high ligation of IMA
a low ligation of IMA
Active Comparator group
Description:
total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
Treatment:
Procedure: a low ligation of IMA

Trial contacts and locations

0

Loading...

Central trial contact

Yueming Sun, PhD; Fumin Zhang, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems